John Cox, Dyne Therapeutics CEO
May 20, 2024 11:35 AM EDT
R&D

Dyne Ther­a­peu­tics sharp­ens case for two mus­cle dis­ease ther­a­pies with up­dat­ed da­ta 

Lei Lei Wu

News Reporter

Dyne Ther­a­peu­tics shared promis­ing clin­i­cal tri­al up­dates from two of its ex­per­i­men­tal RNA med­i­cines for my­oton­ic dy­s­tro­phy type 1 (DM1) and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times